| Record ID | ia:pharmaceuticalpr0002unse |
| Source | Internet Archive |
| Download MARC XML | https://archive.org/download/pharmaceuticalpr0002unse/pharmaceuticalpr0002unse_marc.xml |
| Download MARC binary | https://www.archive.org/download/pharmaceuticalpr0002unse/pharmaceuticalpr0002unse_meta.mrc |
LEADER: 01110cam a2200289 a 4500
001 01edf79d071a4c1993dd6de93eff510a
003 UK-BiTAL
005 20050705145230.0
008 971113s1997 enka 000 ||eng|d
015 $aGB9773082$2bnb
020 $a0749423064
020 $a9282787699 (Luxembourg)
035 $a()0749423064
040 $dUK-BiTAL
082 04 $a338.476151$221
245 00 $aPharmaceutical products /$c[prepared by REMIT].
260 $aLondon :$bKogan Page,$c1997.
300 $axiii, 138p. :$bill. ;$c30 cm.
440 4 $aThe single market review.$nSubseries 1, impact on manufacturing ;$vv.2
500 $aC1-67-96-002-EN-C.
500 $aOn t.p.: European Commission.
504 $aBibliography: p131-138.
650 0 $aDrugs$zEuropean Union countries.
651 0 $aEuropean Union countries$zEconomic integration.
710 2 $aREMIT Consultants Limited.
710 2 $aCommission of the European Communities.$bDirectorate-General for Internal Market and Financial Services.
710 2 $aCommission of the European Communities.$bDirectorate-General for Economic and Financial Affairs.